THERAPY DOSSIER · th-9a5f3ca799e5

MicroRNA-133b co-delivered with Argonaute-2

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32145360 ↗2020Reported benefit

Intravenous delivery of microRNA-133b along with Argonaute-2 enhances spinal cord recovery following cervical contusion in mice.

MouseSpinal cord injuryContusionC57BL6FemaleIntravenous by tail vein injectionBeginning 24 hours after injury

Model: Unilateral moderate contusion at the fifth cervical level

Treatment prevented the injury-induced rise in collagen type 1 alpha 1 and tenascin N and reduced microglial and macrophage recruitment. Functional recovery began around 2 weeks after injury and continued to improve, whereas controls recovered significantly less.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…